,72,92 Importantly, the absence of such enhancer architecture in normal mucosa suggests reduced BRD4 dependency in non-malignant tissue, supporting a potential therapeutic window; this, combined with the dual suppression of viral oncogenes and key host drivers, positions BRD4 inhibition as a uniquely attractive therapeutic strategy in HPV+ HNSCC. Here, BRD4 is linked to head and neck squamous cell carcinoma.